New Zealand Continuous Glucose Monitoring Devices Market Size - Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The New Zealand continuous glucose monitoring devices market is shifting from a self-funded niche to a publicly supported mainstream therapy. Pharmac now funds standalone and pump-linked sensors for people with type 1 diabetes and related conditions, and applications to widen access to type 2 diabetes are under consideration.

Three forces are shaping the market: tighter Pharmac contracting, which consolidates supply around a few brands; the rise of automated insulin delivery, which ties sensors to Tandem and mylife YpsoPump pumps; and a growing diabetes population, projected by researchers to reach 502,358 people by 2044.

In April 2025 Pharmac announced it would list FreeStyle Libre 2 Plus from 1 May 2025 at NZ$99.46 per sensor. In December 2025 it removed Special Authority renewals, and in August 2026 it said Dexcom G6 would be retired by early 2027.

Key Market Trends and Insights

• Funded Libre upgrade: Pharmac listed FreeStyle Libre 2 Plus from 1 May 2025 at NZ$99.46 per sensor ex-GST, with a 15-day wear life and a limit of 28 sensors a year.
• Lower access barriers: From 1 December 2025 Pharmac ended the need to renew Special Authority for continuous glucose monitors, pumps and consumables, which reduces clinic workload and gaps in supply.
• Rising diabetes burden: A study reported in January 2025 estimated 268,248 New Zealanders with diabetes at baseline and 502,358 by 2044, with Asian, Pacific and Maori numbers rising fastest.
• Sensor consolidation: Pharmac said in August 2026 that Dexcom G6 users must move to another funded sensor by early 2027, since G7 now works with both funded pumps.

New Zealand Continuous Glucose Monitoring Devices Market Size and Forecast

The market is moving from episodic self-purchase towards funded, continuous use, with sensors tied ever more closely to automated insulin pumps and phone apps. Sensors lead in value because every user buys them repeatedly, while transmitters, readers and software follow the sensor choice. Software and apps advance fastest as pump algorithms, clinic dashboards and remote sharing create recurring value. Type 1 diabetes remains the largest group, and Type 2 Diabetes grows fastest if funding applications succeed. Community pharmacies dispense most supply, while online and direct-to-patient channels gain share. Auckland remains the largest region, and Canterbury grows quickest on population gains. Regulatory notices, supplier changes and funding rules will shape brand positions more than price alone, even as private purchasers keep a modest but valuable segment.

Key Takeaways: New Zealand Continuous Glucose Monitoring Devices Market

Public Funding Anchors Long-Term Demand

Revenue is on course to expand by about 137% across the decade, from USD 40.00 million in 2025 to USD 94.69 million in 2035 at a 9.0% CAGR. Funded access, an ageing and growing diabetes population and the steady move to automated insulin delivery keep recurring sensor purchases rising.

Apps and Type 2 Access Lead Growth

Sensors hold the largest share, but Software and Apps grow at an estimated 11.4% CAGR and Type 2 Diabetes at an estimated 12.6% CAGR through 2035. Pharmac said in October 2026 that three applications to extend funding to type 2 diabetes are being considered, which would widen the user base sharply.

Supplier Changes Reset Brand Positions

Pharmac is steering users towards fewer, interoperable devices, so sensor and pump brands must align with funded systems. Switching rules and device allowances also shape which brands gain volume.

• Dexcom G6 funding ends in early 2027, with G7 and Libre 3 Plus as replacements
• Medtronic MiniMed 770G consumables stopped being funded on 1 October 2026
• Libre 2 Plus replaced Libre 2, whose funding ran to 1 May 2026

New Zealand Continuous Glucose Monitoring Devices Market Report Summary

Key Insight

Funded access and automated insulin delivery are moving glucose monitoring into routine care. Sensors lead revenue, while software and broader access grow fastest, with Auckland largest and Canterbury quickest.

Key Trends in the New Zealand Continuous Glucose Monitoring Devices Market

The New Zealand continuous glucose monitoring devices market is being reshaped by funding rule changes, sensor consolidation, pump-sensor interoperability and regulatory safety alerts.

October 2026 - Medtronic MiniMed 770G Consumables Cease to Be Funded

• Pharmac said users of funded MiniMed 770G pumps had until 1 October 2026 to move to another funded pump or obtain an exemption.
• Tandem and mylife YpsoPump are the funded alternatives, and a new Special Authority is needed to switch.
• Users with an exceptional circumstances approval for Guardian 4 are automatically approved for MiniMed 770G consumables.

August 2026 - Pharmac Retires Funded Dexcom G6 by Early 2027

• Pharmac published on 4 August 2026 that Dexcom G6 users must change to another funded sensor by early 2027.
• The Dexcom G7 and FreeStyle Libre 3 Plus are the replacements, and G7 now works with both funded pumps.
• A person switching after four G6 devices can receive up to 40 G7 devices until their Special Authority anniversary.

June 2026 - Medsafe Issues Alert on Dexcom G7 Sensor Lots

• Medsafe published the alert on 25 June 2026 for lots 1725204004 and 1725069002, marked for disposal in the United States.
• It reported no evidence the sensors were in New Zealand, and advised buyers from overseas websites to check lot numbers.
• New Zealand Medical and Scientific, which supplies G7 locally, stated it had not distributed affected sensors.

May 2025 - FreeStyle Libre 2 Plus Becomes the Funded Standalone Abbott Sensor

• Pharmac listed the sensor from 1 May 2025 at NZ$99.46 each, supplied by Abbott Laboratories NZ, after announcing the decision on 11 April 2025.
• It lasts 15 days, one day longer than Libre 2, and funding allows 28 sensors a year, six per prescription.
• Libre 2 stayed funded until 1 May 2026 so pharmacists could complete claims during the changeover.

Key Insight

Consolidation around interoperable funded systems, retirement of older sensors and pump supplier changes are the main structural forces, while safety alerts and supply continuity remain the main risks.

Recent Market Developments in the New Zealand Continuous Glucose Monitoring Devices Market

Recent developments, presented from the most recent, show type 2 funding applications, improved access rules, global supplier results and new sensor technology that may reach New Zealand.

October 2026 - Pharmac Considers Three Applications to Fund Sensors for Type 2 Diabetes

• Pharmac's comparison page, updated in October 2026, says continuous glucose monitors are not funded for type 2 diabetes.
• Three applications to change this are being considered, and Diabetes New Zealand continues to campaign for access for all insulin users.
• A positive outcome would add a large group of users to a market now centred on type 1 diabetes.

July 2026 - Abbott Reports Continuous Glucose Monitor Sales Up 11.0% in Second Quarter

• Abbott reported on 16 July 2026 that continuous glucose monitor sales grew 11.0% in the quarter.
• International diabetes care sales reached USD 1,326 million, up 11.7% on a reported basis.
• Strong global demand supports supply and investment for Libre products sold in New Zealand through Mediray.

May 2026 - Abbott Wins CE Mark for Libre Duo Glucose and Ketone Sensor

• Abbott announced in May 2026 a CE Mark for Libre Duo, described as the first dual glucose and ketone wearable sensor.
• The sensor flags rising ketones that can lead to diabetic ketoacidosis, a risk for people with type 1 diabetes.
• No New Zealand launch has been announced, so Medsafe and Pharmac steps would precede any local availability.

April 2026 - Dexcom Reports International Revenue Up 26% in First Quarter

• Dexcom said on 30 April 2026 that international revenue rose to USD 359.6 million, up 26% reported and 17% organically.
• Total first-quarter revenue reached USD 1.192 billion, and the G7 15 Day sensor was expanded across all United States channels.
• Rising overseas demand supports Dexcom's New Zealand distribution through its local company in Auckland.

Key Insight

Wider funding applications, strong supplier results and new sensor technology show growing momentum, while local access still depends on Pharmac decisions and regulatory approvals.

New Zealand Continuous Glucose Monitoring Devices Industry Segmentation

The Expert Market Research’s report on the New Zealand Continuous Glucose Monitoring Devices Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Component

• Sensors
• Transmitters
• Receivers and Display Devices
• Software and Apps
• Others

Sensors lead on value, in our estimate, because each user buys them every 10 to 15 days, as Pharmac's 28-sensor annual limit for Libre 2 Plus from 1 May 2025 shows. Transmitters grow steadily with reusable and pump-linked systems, while Dexcom G7 integrates the transmitter into the sensor. Receivers and Display Devices include dedicated readers, which Pharmac said in August 2025 remain unchanged for Libre 2 Plus alongside its phone app. Software and Apps grow fastest at an estimated 11.4% CAGR through 2035, as the Libre app update advised for 27 October 2026 and pump algorithms such as Control-IQ and CamAPS FX show.

Market Breakup by Diabetes Type

• Type 1 Diabetes
• Type 2 Diabetes
• Others (incl. gestational and monogenic)

Type 1 Diabetes leads on value, in our estimate, because Pharmac's Special Authority for standalone sensors, updated for Libre 2 Plus in April 2025, centres on this group. Type 2 Diabetes grows fastest at an estimated 12.6% CAGR through 2035, since three funding applications were being considered in October 2026 and self-funded use is rising. Others include type 3c, monogenic and neonatal diabetes, which Pharmac also covers where an endocrinologist expects benefit. Researchers reported in January 2025 that 268,248 people had diabetes at baseline.

Market Breakup by Distribution Channel

• Community Pharmacies
• Hospital and Clinic Pharmacies
• Online and Direct-to-Patient
• Others

Community Pharmacies lead, in our estimate, because funded prescriptions are collected there, and Pharmac told pharmacists in August 2026 to prompt Dexcom G6 users to see a prescriber. Hospital and Clinic Pharmacies serve pump starts and paediatric teams, including the pump-linked Libre 3 Plus, which Mediray says is supplied only to funded automated insulin delivery users. Online and Direct-to-Patient grows fastest at an estimated 10.3% CAGR through 2035, as Dexcom runs a Pharmac funding support service from Ellerslie, Auckland. Others cover specialist clinics and community programmes.

Market Breakup by Region

• Auckland
• Wellington
• Canterbury
• Waikato
• Others

Auckland dominates, in our estimate, with the largest population, the main distributor base at Ellerslie and the busiest specialist diabetes services, and grows at an estimated 8.7% CAGR through 2035 from a large base. Stats NZ reported in October 2025 that Auckland grew 1.0% in the year to June 2025. Canterbury is fastest at an estimated 9.8%, after it rose 1.1% to 698,200 people. Waikato grows at 9.5% on 1.0% growth. Wellington grows at 8.2% after flat population growth, and Others at 9.1%.

Competitive Landscape in the New Zealand Continuous Glucose Monitoring Devices Market

Competition combines global sensor makers, pump partners and local distributors under Pharmac contracts. Entry barriers include Medsafe approval, Pharmac listing, interoperability with funded pumps, app compatibility and relationships with specialist diabetes teams and pharmacies.

Dexcom

Dexcom, based in San Diego, makes the G7 and ONE+ sensors, supplied in New Zealand by New Zealand Medical and Scientific from Ellerslie, Auckland. Both are Pharmac-funded, with up to 40 sensors a year. In June 2026 Medsafe published a Dexcom alert on two G7 lots, noting none were distributed locally. Dexcom reported in April 2026 that international revenue rose 26% in the first quarter, and Pharmac set G6 retirement for early 2027.

Abbott

Abbott, based in Abbott Park, Illinois, sells FreeStyle Libre sensors in New Zealand through Abbott Laboratories NZ and distributor Mediray. Pharmac listed Libre 2 Plus from 1 May 2025 at NZ$99.46 per sensor, and Libre 3 Plus is funded for automated insulin delivery users. In July 2026 Abbott reported continuous glucose monitor sales up 11.0%, and in May 2026 it announced a CE Mark for the Libre Duo glucose and ketone sensor.

Tandem Diabetes Care

Tandem Diabetes Care, based in San Diego, supplies the t:slim X2 pump with Basal-IQ and Control-IQ in New Zealand, a Pharmac-funded system distributed by New Zealand Medical and Scientific. Pharmac said in August 2026 that Dexcom G7 works with both funded pumps, and that Medtronic 770G users moving to Tandem or YpsoPump need a new Special Authority. The pump ties users to interoperable Dexcom and Libre sensors.

Ypsomed

Ypsomed, based in Burgdorf, Switzerland, makes the mylife YpsoPump, funded by Pharmac with the CamAPS FX algorithm and supplied locally by Pharmaco. Pharmac funded mylife YpsoPump Orbit Soft infusion sets from 1 August 2026 in four sizes. The pump works with Dexcom G7 and FreeStyle Libre 3 Plus, so it drives sensor demand, and Pharmac named it as an alternative for Medtronic MiniMed 770G users in October 2026.

Other players operating in the New Zealand continuous glucose monitoring devices market include Medtronic, Mediray, Pharmaco, Roche Diabetes Care, and Senseonics, alongside independent pharmacies, diabetes clinics, importers and online retailers supplying sensors, accessories and support to patients across New Zealand.

Key Insight

Competition rests on Pharmac listing, pump interoperability, app quality and clinic relationships rather than price alone, while supplier retirements and contract changes can quickly reshape brand positions.